# NMN vs NR: NAD+ Precursors in the Research Literature | NAD+

> NMN vs NR compared: distinct uptake routes, dose-response data, and clinical depth. NR raised blood NAD+ 22/51/142%; NMN 250 mg/day improved muscle insulin sensitivity. Cited.

Two NAD+ building blocks, two uptake routes, two evidence profiles — read side by side, with the supplement-versus-precursor distinction kept exact.

## The short version

NMN vs NR is the comparison every NAD+ reader eventually reaches. Both are precursors — building blocks the body turns into NAD+ — and both are the *oral* answer to a basic problem: you cannot usefully swallow NAD+ itself, because it is too big to absorb intact [8]. NR (nicotinamide riboside) has the deepest controlled safety data and a clean dose-response on the NAD+ biomarker [4]. NMN (nicotinamide mononucleotide) sits one step closer to NAD+ and has the most-cited functional human result [1]. Neither has proven it changes hard clinical outcomes in people [14].

## NAD+ vs NMN: why precursors are the oral route

Start with the distinction that the whole page rests on. NAD+ itself is large and charged, poorly absorbed intact, and not freely taken up by most cells [8][9]. NMN is a *precursor* — a smaller molecule one biochemical step from NAD+ that the body readily converts. So "NAD+ vs NMN" is not two interchangeable supplements: oral NAD+ is the poorly-absorbed parent molecule, and NMN is the studied oral building block. This is why a trial of oral NMN must never be described as "taking NAD+" — it measured a precursor, and the precursor is the point.

## Distinct uptake routes

NMN and NR enter cells differently [8]. In mice, NMN is rapidly absorbed in the gut and raises NAD+ in peripheral tissues within minutes; a dedicated transporter (Slc12a8) has been described for direct NMN uptake. NR is taken up after phosphorylation by NRK kinases (NRK1/NRK2), routing through NMN on its way to NAD+, but NR is comparatively unstable in murine plasma and degrades toward nicotinamide [8]. Both intermediates raise NAD+ across multiple tissues, and both show larger responses in aged animals than young — consistent with correcting an age-related deficit [8]. The routes differ; the destination — the NAD+ pool — is shared.

## Dose-response and clinical depth

On controlled human evidence, the two precursors are studied differently. **NR** has the cleanest dose-response on the NAD+ biomarker: `100`, `300` and `1000 mg/day` for 8 weeks raised whole-blood NAD+ by `22%`, `51%` and `142%`, with no flushing and no significant adverse-event excess versus placebo [4]. **NMN** has the most-cited *functional* readout: `250 mg/day` for 10 weeks improved muscle insulin sensitivity in prediabetic postmenopausal women [1], and a multicenter `300-900 mg/day` trial raised blood NAD+ at every dose and improved walking distance, naming `600 mg/day` optimal [3]. In rodents, NMN `500 mg/kg/day` improved glucose handling and NR `400 mg/kg/day` cut diet-induced weight gain and liver fat [9]. Both reliably raise NAD+; neither has shown a hard clinical-endpoint benefit in humans [14].

## Is taking NAD orally effective?

Oral NAD+ itself is poorly absorbed intact, so most researchers favor precursors [8][9]. Oral NMN and NR reliably and dose-dependently raise whole-blood NAD+ in randomized trials — NR by `22%`/`51%`/`142%` at `100`/`300`/`1000 mg/day` [4] — though clinical-endpoint benefits are mixed and still preliminary in humans [14]. The biomarker responds; the downstream payoff is unproven.

## The regulatory wrinkle on NMN

One difference between the two precursors is regulatory, not biochemical. The FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was previously authorized for investigation as a drug — an unsettled *marketplace dispute* over NMN's supplement status, not a ban and not a safety finding [14]. NR has not faced the same challenge. This digest presents the dispute as ongoing uncertainty about how NMN may be sold, nothing more. Beyond that, supplement-grade purity varies between products and third-party testing is not guaranteed for either precursor.

---

An orbital reading of the NAD+ literature — the coenzyme at the core, its precursors NMN and NR held apart from the molecule itself, and the human, rodent and gap evidence each logged to source; no clinic behind the console and nothing here infused, dispensed or sold.